Dayton's adult obesity rate against the lowest median household income of any city we cover, the local call-for-pricing pattern, a fresh federal shortage designation, and Ohio Medicaid's exclusion, every figure sourced.
42.9% of adults inside Dayton city limits have obesity in the CDC's PLACES place-level estimates (2025 release, 2023 survey data) 1, nearly ten points above the national adult rate of 33.1% in the CDC's 2024 BRFSS estimates 2. Those two figures come from different survey years, so we read the gap as a direction rather than a decimal. Ohio statewide sits at 36.9% 2.
Set that against median household income in Dayton of $45,846 in the 2024 ACS one-year estimates 6, the lowest of any city we have written about. The near-highest obesity burden paired with the lowest incomes is the local story here, and it is an affordability story before it is a clinical one.
We checked three providers marketing GLP-1 care to Dayton. The two with a physical presence in the area, Dr. Roz Total Health & Wellness in Miamisburg and Vytality Blu Health & Medspa on Far Hills Avenue, published no GLP-1 prices as of our August 2026 check; in both cases learning the cost requires booking an appointment 1112. That is a common and entirely legitimate consult-first model, but it does put the number behind a scheduling step.
The one provider posting figures is online. Coby Health, which markets to Dayton, advertises compounded semaglutide at $159 for month one and $399 for the first 12 weeks, about $133 per month, rising to $249 per month at the highest doses, with free delivery throughout the Miami Valley 10. Dose-escalation pricing means the number you sign up for is not the number you pay six months in, because titration normally moves upward.
For a comparison shopper in a city with a $45,846 median household income, that combination is expensive in time and in uncertainty: two appointments to obtain two quotes, and a third price that changes as your dose does. If you take an afternoon off work for each in-person consult and still cannot compare the two numbers side by side until both visits are done, the search itself has a cost, and it lands hardest on the households the obesity figure describes.
It also makes budgeting hard in a specific way. A dose-escalation schedule is normal clinical practice: most people start low and move up over the first several months. A price that follows the dose upward therefore means the figure quoted at enrollment is close to a floor, not an average, and the escalated-dose figure is the one worth planning around.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
In this market, a posted flat price is itself the differentiator, and we will say that plainly. It is the same figure at every dose and the same figure in every state we serve, so it is not a Dayton offer, not an introductory rate, and not a number that moves when your prescriber titrates you up.
On June 18, 2025, HRSA designated Dayton/Riverside/West Dayton a Low-Income primary-care Health Professional Shortage Area with a score of 15 7. The date matters: the federal record describes a shortage that is current, not a legacy designation carried forward from years ago. A low-income designation is narrower than a whole-county one, because it applies to the residents least able to absorb a cash price in the first place. Dayton's uninsured rate is 9.4% in the 2024 ACS one-year estimates 5, which compounds the same access problem.
The specialist geography points outward from the city. Premier Health's weight-loss program locations are in Englewood, Centerville, and Liberty Township 9, all suburban, which turns care into a drive for residents of West Dayton and Riverside who may not have a reliable one. Obesity medicine is also a maintenance specialty rather than a one-visit specialty: intake, titration checks, and refills recur, so a single trip to the suburbs is really a standing monthly trip.
That is the gap telehealth closes. With Astra, a licensed provider reviews your intake usually within 24 hours, medication ships overnight in discreet packaging, there are no clinic visits, you can message your care team at any point in treatment, and you are only charged if a provider prescribes.
Ohio Medicaid does not cover GLP-1 medications for weight loss alone. Coverage is limited to diabetes indications, so a member whose only indication is obesity is paying cash 8. That single line explains most of the cash-pay market in Montgomery County: the funding gap it leaves is exactly the gap local clinics and online sellers are pricing into.
Commercial plans vary widely. Some Ohio employer plans cover Wegovy or Zepbound with prior authorization, others carve out weight-loss drugs entirely, and a growing number cover them only alongside a required lifestyle or coaching program. The only reliable check is your own plan's formulary and its prior-authorization criteria, and it is worth doing before paying cash, because a covered brand medication with a manageable copay beats any cash price.
Separately, Ohio's Board of Pharmacy holds the strictest posture toward compounded GLP-1s of any state we serve, which shapes what a compounding pharmacy may dispense to an Ohio address and what a provider may prescribe. The full detail, with citations, is on the Ohio GLP-1 hub.
Astra's provider group and partner pharmacies are licensed to serve patients in Ohio, the Miami Valley included, subject to the Ohio Board of Pharmacy conditions described on the Ohio GLP-1 hub. Ohio's telehealth statute and compounding rules are set out there in full.
Astra treats patients in Ohio through state-licensed physicians.
Most use a consult-first model, which is common in medical weight management: cost depends on the medication, the dose, and whether labs and follow-up visits are bundled, so the clinic quotes you after an appointment. Of the three area providers we checked in August 2026, the two in-person ones published no GLP-1 prices at all. It is a normal business practice, not a red flag, but it does mean comparison shopping takes appointments. Astra posts its price instead: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans.
On the posted figures, yes. Coby Health, which markets to Dayton, advertises $159 for the first month and about $133 per month across the first 12 weeks, rising to $249 per month at the highest doses. Astra's compounded semaglutide is $68 per month on the 12-month plan and does not change when your dose is escalated. That is a national price rather than a Dayton deal: the same number applies in Columbus, in Dallas, and everywhere else we operate.
Not for weight loss alone. Ohio Medicaid limits GLP-1 coverage to diabetes indications, so a member whose only indication is obesity will not have Wegovy or Zepbound covered for that purpose. Commercial plans vary, so check your formulary. Coverage and state rules are detailed on our Ohio GLP-1 hub at /glp-1/ohio/.
Sometimes, and Ohio is the strictest state we serve on this point. The Ohio Board of Pharmacy does not permit compounding what are essentially copies of commercially available FDA-approved products, allows only narrow patient-specific 503A exceptions such as a documented clinical need the approved product cannot meet, and prohibits salt forms such as semaglutide sodium or acetate. Whether a compounded prescription is appropriate for you is a clinical determination a licensed provider makes. The verified detail and citations are on our Ohio GLP-1 hub at /glp-1/ohio/.
No. Ohio Revised Code 4743.09 lets a licensed provider treat an Ohio patient by telehealth, including the initial visit, with no prior in-person exam required to prescribe non-controlled medications. The full statutory detail is in the telehealth section of our Ohio GLP-1 hub at /glp-1/ohio/.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.